Clinical trial
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine…
NCT00494780 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00494780 |
|---|---|
| Title | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients |
| Official title | An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL). |
| Acronym | MUNIN |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular |
| Intervention type | Drug |
| Interventions | Ofatumumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Prednisone or equivalent |
| Enrollment | 59 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | Jul 2, 2007 |
| Last update posted | Jul 11, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: